{
  "abstract": "Objective Buprenorphine is an atypical opioid with analgesic efficacy and a more favorable safety profile than conventional opioids or tramadol. In 2019, access to on-label buprenorphine formulations was limited in comparison to conventional opioids, despite evidence supporting buprenorphine’s first-line analgesic use. Considering recent policy changes increasing buprenorphine accessibility, we determined differences in unrestricted insurance coverage between buprenorphine, conventional opioids, and other atypical opioids.Methods We used data from Managed Market Insights and Technology’s Coverage Search and Kaiser Family Foundation to generate estimates on percentages of US-covered lives with unrestricted access to oxycodone, morphine, tramadol, tapentadol, generic and on-label transdermal buprenorphine, on-label buccal buprenorphine, and on-label sublingual buprenorphine/naloxone in 2024.Results 79.7% of commercial and 99.1% of Medicare lives had unrestricted oxycodone access. Morphine access was unrestricted for 45.7% of commercial and 62.8% of Medicare lives. Unrestricted access to tramadol was available for 88.2% of commercial and 96.3% of Medicare lives. 37.3% of commercial and 10.1% of Medicare lives had unrestricted tapentadol access. Unrestricted access to on-label transdermal buprenorphine was available for 21.0% of commercial and 2.59% of Medicare lives. Generic transdermal buprenorphine was available for 52.1% of commercial and 30.0% of Medicare lives. Buccal buprenorphine was available without restriction for 52.7% of commercial and 19.8% of Medicare lives. Sublingual buprenorphine/naloxone had unrestricted coverage for 34.6% of commercial and 32.7% of Medicare lives.Conclusions Access to buprenorphine formulations was limited in comparison to other opioids. This study emphasizes a need for commercial and Medicare health insurance plans to broaden buprenorphine coverage.",
  "authors": [
    {
      "affiliations": [
        "Pain Labs, New Albany, Ohio, USA"
      ],
      "name": "Bennett Andrassy"
    },
    {
      "affiliations": [
        "Pain Labs, New Albany, Ohio, USA"
      ],
      "name": "Junaid Mukhdomi"
    },
    {
      "affiliations": [
        "Brown University Warren Alpert Medical School, Providence, Rhode Island, USA"
      ],
      "name": "Nidhi Bhaskar"
    },
    {
      "affiliations": [
        "Pain Labs, New Albany, Ohio, USA"
      ],
      "name": "Marcus Harris"
    },
    {
      "affiliations": [
        "Pain Labs, New Albany, Ohio, USA"
      ],
      "name": "Taif Mukhdomi"
    }
  ],
  "title": "Unrestricted insurance coverage of buprenorphine formulations remains sparse in comparison to conventional opioids",
  "uid": "62c9e546-f533-51b1-8a0e-aa847f0ce6f4"
}